利妥昔单抗治疗儿童激素依赖型肾病综合征的研究进展
Research Progress on Rituximab in the Treatment of Steroid-Dependent Nephrotic Syndrome in Children
DOI: 10.12677/acm.2025.1551394, PDF,   
作者: 陈刘同, 李 秋*：重庆医科大学附属儿童医院肾脏内科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿童代谢与炎症性疾病重庆市重点实验室，重庆
关键词: 原发性肾病综合征；儿童；激素依赖；利妥昔单抗；Primary Nephrotic Syndrome； Child； Steroid-Dependent； Rituximab
摘要: 原发性肾病综合征(primary nephrotic syndrome, PNS)是儿童最为常见的肾小球疾病之一。大多数PNS患儿对糖皮质激素治疗反应良好，但仍有超过四分之一的患儿会进展为激素依赖型肾病综合征(steroid-dependent NS, SDNS)，如何选用有效的治疗方案仍是目前临床治疗的难点之一。利妥昔单抗(RTX)应用于治疗儿童SDNS已取得良好的疗效，但各个中心对RTX治疗方案的选择各不相同，疗效亦有差异。本文旨在对RTX治疗儿童SDNS的有效性、安全性等方面进行综述。
Abstract: Primary nephrotic syndrome (PNS) is one of the most prevalent glomerular disorders in children. While the majority of pediatric PNS patients exhibit favorable responses to glucocorticoid therapy, over one-quarter progress to steroid-dependent nephrotic syndrome (SDNS), posing significant challenges in clinical management. Rituximab (RTX) has demonstrated promising efficacy in treating pediatric SDNS, though significant variations exist in therapeutic protocols across different medical centers, resulting in divergent clinical outcomes. This review aims to comprehensively evaluate the therapeutic effectiveness and safety profile of RTX in the management of childhood SDNS.
文章引用：陈刘同, 李秋. 利妥昔单抗治疗儿童激素依赖型肾病综合征的研究进展[J]. 临床医学进展, 2025, 15(5): 466-472. https://doi.org/10.12677/acm.2025.1551394

参考文献

[1] Eddy, A.A. and Symons, J.M. (2003) Nephrotic Syndrome in Childhood. The Lancet, 362, 629-639. [Google Scholar] [CrossRef] [PubMed]
[2] Iijima, K., Sako, M. and Nozu, K. (2017) Rituximab for Nephrotic Syndrome in Children. Clinical and Experimental Nephrology, 21, 193-202. [Google Scholar] [CrossRef] [PubMed]
[3] Blanco, E., Pérez-Andrés, M., Arriba-Méndez, S., Contreras-Sanfeliciano, T., Criado, I., Pelak, O., et al. (2018) Age-Associated Distribution of Normal B-Cell and Plasma Cell Subsets in Peripheral Blood. Journal of Allergy and Clinical Immunology, 141, 2208-2219.E16. [Google Scholar] [CrossRef] [PubMed]
[4] Watts, A.J.B., Keller, K.H., Lerner, G., Rosales, I., Collins, A.B., Sekulic, M., et al. (2022) Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. Journal of the American Society of Nephrology, 33, 238-252. [Google Scholar] [CrossRef] [PubMed]
[5] Chan, E.Y., Yap, D.Y., Colucci, M., Ma, A.L., Parekh, R.S. and Tullus, K. (2023) Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology, 18, 533-548. [Google Scholar] [CrossRef] [PubMed]
[6] 全国儿童常见肾脏病诊治现状调研工作组. 我国儿童激素敏感、复发/依赖肾病综合征诊疗现状的多中心研究[J]. 中华儿科杂志, 2014, 52(3): 194-200.
[7] Larkins, N.G., Hahn, D., Liu, I.D., Willis, N.S., Craig, J.C. and Hodson, E.M. (2024) Non-Corticosteroid Immunosuppressive Medications for Steroid-Sensitive Nephrotic Syndrome in Children. Cochrane Database of Systematic Reviews, No. 11, CD002290. [Google Scholar] [CrossRef] [PubMed]
[8] Hodson, E.M. (2000) Corticosteroid Therapy in Nephrotic Syndrome: A Meta-Analysis of Randomised Controlled Trials. Archives of Disease in Childhood, 83, 45-51. [Google Scholar] [CrossRef] [PubMed]
[9] Noone, D.G., Iijima, K. and Parekh, R. (2018) Idiopathic Nephrotic Syndrome in Children. The Lancet, 392, 61-74. [Google Scholar] [CrossRef] [PubMed]
[10] Veltkamp, F., Rensma, L.R. and Bouts, A.H.M. (2021) Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-Analysis. Pediatrics, 148, e2020029249. [Google Scholar] [CrossRef] [PubMed]
[11] 中华医学会儿科学分会肾脏学组. 儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016) [J]. 中华儿科杂志, 2017, 55(10): 729-734.
[12] 杨帆, 蒋小云. 儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016)解读[J]. 中华儿科杂志, 2017, 55(10): 738-742.
[13] Rovin, B.H., Adler, S.G., Barratt, J., Bridoux, F., Burdge, K.A., Chan, T.M., et al. (2021) Executive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 100, 753-779. [Google Scholar] [CrossRef] [PubMed]
[14] Samuel, S., Morgan, C.J., Bitzan, M., Mammen, C., Dart, A.B., Manns, B.J., et al. (2013) Substantial Practice Variation Exists in the Management of Childhood Nephrotic Syndrome. Pediatric Nephrology, 28, 2289-2298. [Google Scholar] [CrossRef] [PubMed]
[15] Rovin, B.H., Adler, S.G., Barratt, J., Bridoux, F., Burdge, K.A., Chan, T.M., et al. (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 100, S1-S276. [Google Scholar] [CrossRef] [PubMed]
[16] Iijima, K., Sako, M., Nozu, K., Mori, R., Tuchida, N., Kamei, K., et al. (2014) Rituximab for Childhood-Onset, Complicated, Frequently Relapsing Nephrotic Syndrome or Steroid-Dependent Nephrotic Syndrome: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet, 384, 1273-1281. [Google Scholar] [CrossRef] [PubMed]
[17] Ahn, Y.H., Kim, S.H., Han, K.H., Choi, H.J., Cho, H., Lee, J.W., et al. (2018) Efficacy and Safety of Rituximab in Childhood-Onset, Difficult-to-Treat Nephrotic Syndrome. A Multicenter Open-Label Trial in Korea. Medicine, 97, e13157. [Google Scholar] [CrossRef] [PubMed]
[18] Basu, B., Sander, A., Roy, B., Preussler, S., Barua, S., Mahapatra, T.K.S., et al. (2018) Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome. A Randomized Clinical Trial. JAMA Pediatrics, 172, 757-764. [Google Scholar] [CrossRef] [PubMed]
[19] Ravani, P., Magnasco, A., Edefonti, A., Murer, L., Rossi, R., Ghio, L., et al. (2011) Short-Term Effects of Rituximab in Children with Steroid-and Calcineurin-Dependent Nephrotic Syndrome. A Randomized Controlled Trial. Clinical Journal of the American Society of Nephrology, 6, 1308-1315. [Google Scholar] [CrossRef] [PubMed]
[20] Ravani, P., Rossi, R., Bonanni, A., Quinn, R.R., Sica, F., Bodria, M., et al. (2015) Rituximab in Children with Steroid-Dependent Nephrotic Syndrome. A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. Journal of the American Society of Nephrology, 26, 2259-2266. [Google Scholar] [CrossRef] [PubMed]
[21] Trautmann, A., Boyer, O., Hodson, E., Bagga, A., Gipson, D.S., Samuel, S., et al. (2023) IPNA Clinical Practice Recommendations for the Diagnosis and Management of Children with Steroid-Sensitive Nephrotic Syndrome. Pediatric Nephrology, 38, 877-919. [Google Scholar] [CrossRef] [PubMed]
[22] Chan, E.Y., Webb, H., Yu, E., Ghiggeri, G.M., Kemper, M.J., Ma, A.L., et al. (2020) Both the Rituximab Dose and Maintenance Immunosuppression in Steroid-Dependent/Frequently-Relapsing Nephrotic Syndrome Have Important Effects on Outcomes. Kidney International, 97, 393-401. [Google Scholar] [CrossRef] [PubMed]
[23] Sacchi, S., Federico, M., Dastoli, G., Fiorani, C., Vinci, G., Clò, V., et al. (2001) Treatment of B-Cell Non-Hodgkin’s Lymphoma with Anti CD 20 Monoclonal Antibody Rituximab. Critical Reviews in Oncology/Hematology, 37, 13-25. [Google Scholar] [CrossRef] [PubMed]
[24] Lee, S.C., Srivastava, R.M., López-Albaitero, A., Ferrone, S. and Ferris, R.L. (2011) Natural Killer (NK):Dendritic Cell (DC) Cross Talk Induced by Therapeutic Monoclonal Antibody Triggers Tumor Antigen-Specific T Cell Immunity. Immunologic Research, 50, 248-254. [Google Scholar] [CrossRef] [PubMed]
[25] Panjideh, H., Müller, G., Koch, M., Wilde, F., Scheu, S., Moldenhauer, G., et al. (2014) Immunotherapy of B‐Cell Non‐Hodgkin Lymphoma by Targeting the Chemokine Receptor CXCR5 in a Preclinical Mouse Model. International Journal of Cancer, 135, 2623-2632. [Google Scholar] [CrossRef] [PubMed]
[26] Godeau, B., Porcher, R., Fain, O., Lefrère, F., Fenaux, P., Cheze, S., et al. (2008) Rituximab Efficacy and Safety in Adult Splenectomy Candidates with Chronic Immune Thrombocytopenic Purpura: Results of a Prospective Multicenter Phase 2 Study. Blood, 112, 999-1004. [Google Scholar] [CrossRef] [PubMed]
[27] Kamel, S., O’Connor, S., Lee, N., Filshie, R., Nandurkar, H. and Tam, C.S. (2010) High Incidence of Pneumocystis jirovecii Pneumonia in Patients Receiving Biweekly Rituximab and Cyclophosphamide, Adriamycin, Vincristine, and Prednisone. Leukemia & Lymphoma, 51, 797-801. [Google Scholar] [CrossRef] [PubMed]
[28] Ravani, P., Lugani, F., Pisani, I., Bodria, M., Piaggio, G., Bartolomeo, D., et al. (2020) Rituximab for Very Low Dose Steroid-Dependent Nephrotic Syndrome in Children: A Randomized Controlled Study. Pediatric Nephrology, 35, 1437-1444. [Google Scholar] [CrossRef] [PubMed]
[29] Ravani, P., Lugani, F., Drovandi, S., Caridi, G., Angeletti, A. and Ghiggeri, G.M. (2021) Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults. A Randomized Clinical Trial. JAMA Pediatrics, 175, 631-632. [Google Scholar] [CrossRef] [PubMed]
[30] Kari, J.A., Alhasan, K.A., Albanna, A.S., Safdar, O.Y., Shalaby, M.A., Böckenhauer, D., et al. (2020) Rituximab versus Cyclophosphamide as First Steroid-Sparing Agent in Childhood Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome. Pediatric Nephrology, 35, 1445-1453. [Google Scholar] [CrossRef] [PubMed]
[31] Zhu, Y., Chen, J., Zhang, Y., Wang, X. and Wang, J. (2024) Immunosuppressive Agents for Frequently Relapsing/Steroid-Dependent Nephrotic Syndrome in Children: A Systematic Review and Network Meta-Analysis. Frontiers in Immunology, 15, Article 1310032. [Google Scholar] [CrossRef] [PubMed]
[32] Chang, D., Gong, M., Liu, C., Zhang, Q., Hu, Z. and Li, Z. (2021) Efficacy and Safety of Rituximab for Childhood Refractory Nephrotic Syndrome: A Meta-Analysis of Randomized Controlled Trials. Medicina Clínica, 157, 418-426. [Google Scholar] [CrossRef] [PubMed]
[33] Ang, J.F., Widjanarko, N.D. and Ekaputra, A. (2024) Rituximab versus Tacrolimus as Corticosteroid-Sparing Therapy for Children with Steroid-Dependent Nephrotic Syndrome: A Systematic Review and Meta-Analysis of Randomized and Nonrandomized Controlled Trials. Tzu Chi Medical Journal, 36, 319-329. [Google Scholar] [CrossRef] [PubMed]
[34] Ito, S., Kamei, K., Ogura, M., Sato, M., Fujimaru, T., Ishikawa, T., et al. (2011) Maintenance Therapy with Mycophenolate Mofetil after Rituximab in Pediatric Patients with Steroid-Dependent Nephrotic Syndrome. Pediatric Nephrology, 26, 1823-1828. [Google Scholar] [CrossRef] [PubMed]
[35] Fujinaga, S., Someya, T., Watanabe, T., Ito, A., Ohtomo, Y., Shimizu, T., et al. (2013) Cyclosporine versus Mycophenolate Mofetil for Maintenance of Remission of Steroid-Dependent Nephrotic Syndrome after a Single Infusion of Rituximab. European Journal of Pediatrics, 172, 513-518. [Google Scholar] [CrossRef] [PubMed]
[36] Fujinaga, S., Hirano, D., Mizutani, A., Sakuraya, K., Yamada, A., Sakurai, S., et al. (2017) Predictors of Relapse and Long-Term Outcome in Children with Steroid-Dependent Nephrotic Syndrome after Rituximab Treatment. Clinical and Experimental Nephrology, 21, 671-676. [Google Scholar] [CrossRef] [PubMed]
[37] Iijima, K., Sako, M., Oba, M., Tanaka, S., Hamada, R., Sakai, T., et al. (2022) Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome. Journal of the American Society of Nephrology, 33, 401-419. [Google Scholar] [CrossRef] [PubMed]
[38] Basu, B., Erdmann, S., Sander, A., Mahapatra, T.K.S., Meis, J. and Schaefer, F. (2023) Long-Term Efficacy and Safety of Rituximab versus Tacrolimus in Children with Steroid Dependent Nephrotic Syndrome. Kidney International Reports, 8, 1575-1584. [Google Scholar] [CrossRef] [PubMed]
[39] Inoki, Y., Kamei, K., Nishi, K., Sato, M., Ogura, M. and Ishiguro, A. (2022) Incidence and Risk Factors of Rituximab-Associated Hypogammaglobulinemia in Patients with Complicated Nephrotic Syndrome. Pediatric Nephrology, 37, 1057-1066. [Google Scholar] [CrossRef] [PubMed]
[40] Mathew, G., Sinha, A., Ahmed, A., Grewal, N., Khandelwal, P., Hari, P., et al. (2022) Efficacy of Rituximab versus Tacrolimus in Difficult-to-Treat Steroid-Sensitive Nephrotic Syndrome: An Open-Label Pilot Randomized Controlled Trial. Pediatric Nephrology, 37, 3117-3126. [Google Scholar] [CrossRef] [PubMed]
[41] Bazargani, B., Noparast, Z., Khedmat, L., Fahimi, D., Esfahani, S.T., Moghtaderi, M., et al. (2022) Efficacy of Rituximab Therapy in Children with Nephrotic Syndrome: A 10-Year Experience from an Iranian Pediatric Hospital. BMC Pediatrics, 22, Article No. 36. [Google Scholar] [CrossRef] [PubMed]
[42] Bertrand, Q., Mignot, S., Kwon, T., Couderc, A., Maisin, A., Cambier, A., et al. (2022) Anti-Rituximab Antibodies in Pediatric Steroid-Dependent Nephrotic Syndrome. Pediatric Nephrology, 37, 357-365. [Google Scholar] [CrossRef] [PubMed]
[43] Athni, T.S. and Barmettler, S. (2023) Hypogammaglobulinemia, Late-Onset Neutropenia, and Infections Following Rituximab. Annals of Allergy, Asthma & Immunology, 130, 699-712. [Google Scholar] [CrossRef] [PubMed]
[44] Mahmoud, I., Jellouli, M., Boukhris, I., Charfi, R., Ben Tekaya, A., Saidane, O., et al. (2017) Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. The Journal of Pediatrics, 187, 213-219.e2. [Google Scholar] [CrossRef] [PubMed]
[45] Loomba, R. and Liang, T.J. (2017) Hepatitis B Reactivation Associated with Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology, 152, 1297-1309. [Google Scholar] [CrossRef] [PubMed]

为你推荐